Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria (FOSPIP)
A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria
Sponsor: Centre de Recherche Médicale de Lambaréné
Listed as NCT02198807, this PHASE2 trial focuses on Oral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria and remains ongoing. Sponsored by Centre de Recherche Médicale de Lambaréné, it has been updated 6 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre de Recherche Médicale de Lambaréné
- Jomaa Pharma GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.